Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

PURPOSE: To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males. METHODS: Six phase I studies were conducted in European, Chinese, and Japanese males. Subjects received oral vericiguat as a single dose (0.5–15.0 mg solution [for first-in-human study] o...

Descripción completa

Detalles Bibliográficos
Autores principales: Boettcher, Michael, Thomas, Dirk, Mueck, Wolfgang, Loewen, Stephanie, Arens, Erich, Yoshikawa, Kenichi, Becker, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935833/
https://www.ncbi.nlm.nih.gov/pubmed/33125516
http://dx.doi.org/10.1007/s00228-020-03023-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935833/
https://www.ncbi.nlm.nih.gov/pubmed/33125516
http://dx.doi.org/10.1007/s00228-020-03023-7

Ejemplares similares